ArticleScientific reports2025
SIRT1 mediated autophagy enhancement by Lactobacillus fermentum derived oligosaccharides accelerates wound healing in biofilm associated infection.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study explores the structural elucidation, antimicrobial properties, and wound-healing potential of a novel oligosaccharide, OligoF, derived from Lactobacillus fermentum. Structural analysis using paper chromatography, and 1D & 2D NMR spectroscopy indicated that OligoF is a linear tetrasaccharide comprising β-D-glucose, α-L-rhamnose, and D-glucuronic acid in a defined sequence. This structural elucidation was further confirmed by key chemical shifts, coupling constants, and glycosidic linkage assignments. OligoF exhibited potent antibacterial activity against multidrug-resistant Pseudomonas aeruginosa isolates, demonstrating inhibition zones of 60-63 mm, a minimum inhibitory concentration (MIC) of 16 µg/mL, and a minimum bactericidal concentration (MBC) of 32 µg/mL. Biofilm eradication assays revealed a significant reduction in biofilm viability by ~ four-fold at sub-MIC concentrations, as evidenced by scanning electron microscopy. OligoF-treated biofilms displayed notable disruption of extracellular matrix and severe bacterial cell distortion compared to untreated controls. In vivo wound-healing assays in rats showed that OligoF significantly reduced wound area and enhanced skin repair compared to untreated controls. Treatment with OligoF notably increased the concentration and gene expression of SIRT1 as well as upregulated the gene expression of beclin1 and ATG5 which are critical regulators of autophagy and cellular repair processes. Histopathological analysis corroborated these findings, revealing enhanced re-epithelialization, granulation tissue formation, and vascularized connective tissue deposition in OligoF-treated wounds. These findings underscore the potential of OligoF as a multifunctional agent with antibacterial and wound-healing properties, paving the way for its application in managing multidrug-resistant infections and promoting tissue repair.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.